Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.35 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.35 |
| ▸ | PTPRC | P08575 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPRA | P18433 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | PTPRE | P23469 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780775 | 1.00 | CES2 (0.38) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL1429996 | 0.80 | CES2 (0.38) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL1429997 | 0.80 | CES2 (0.38) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL3768874 | 0.72 | MAPT (0.43) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL3768873 | 0.72 | MAPT (0.43) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL130575 | 0.72 | PTPN1 (0.48) | PTPN1MAP2K1MAP2K2 | |
| SCHEMBL13774363 | 0.71 | CES2 (0.38) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL78403 | 0.70 | MAP2K1 (0.53) | CES2CES1PTPN1MAP2K1MAP2K2 | |
| SCHEMBL10518508 | 0.70 | CES2 (0.51) | CES2CES1 | |
| SCHEMBL12961518 | 0.69 | MEN1 (0.41) | CES2CES1MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | CES2 866/4885CES1 1799/4885PTPN1 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.